Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

74.74 -1.05 (-1.39%)
Streaming Delayed Price Updated: 10:26 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Powerful UnR Session As All Four Market Indices Lockstep Rally Into The Close; Bear Trap Set? ↗
In this video lesson, I review the overall market, the recent bearish sentiment, and one new swing trade idea for Monday's session. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
From GeneDx
Via Business Wire
News headline image
Top Biotech GeneDx Catapults 42% After Obliterating Earnings Forecasts ↗
GeneDx stock catapulted more than 40% on Tuesday after the top-notch biotech smashed fourth-quarter expectations. 
Via Investor's Business Daily
News headline image
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings ↗
 
Via Benzinga
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
From GeneDx
Via Business Wire
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 18, 2025 ↗
 
Via Benzinga
News headline image
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
From GeneDx
Via Business Wire
News headline image
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
From GeneDx
Via Business Wire
News headline image
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
From GeneDx
Via Business Wire
News headline image
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
From GeneDx
Via Business Wire
News headline image
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name. 
Via MarketBeat
News headline image
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
News headline image
Stocks Moving Lower Despite Encouraging Inflation Data ↗
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
GeneDx Announces Preliminary 2024 Financial Results
From GeneDx
Via Business Wire
News headline image
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
From GeneDx
Via Business Wire
News headline image
I’m Not Worried About This Pullback ↗
Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree. 
Via Talk Markets
Topics Cryptocurrencies Stocks / Equities
News headline image
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
From GeneDx
Via Business Wire
News headline image
IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development ↗
GeneDx provides whole and exome gene sequencing to identify rare diseases. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Focus On High Cash Flow Companies. You Are The Company You Keep. ↗
There are too many stocks acting well to expect a bear market right now. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly ↗
Energy plays, a biotech and a brokerage also are flashing buy signals or setting up. 
Via Investor's Business Daily
News headline image
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday ↗
US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters. 
Via Benzinga
News headline image
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
From GeneDx
Via Business Wire
News headline image
Best Performing Stocks Of 2024 ↗
A look at the some of best performing stocks in 2024 of current Russell 3,000 members. 
Via Talk Markets
Topics Stocks / Equities
News headline image
The Top 5 Mid Cap Stocks Of 2024 ↗
These high-fliers are on the leading edge of innovation. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.